Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) [Phase 3]

View source ↗

Summary

The TENAYA Phase 3 trial evaluating faricimab for neovascular age-related macular degeneration has completed and posted results in 2022, reporting efficacy and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Vabysmo (faricimab-svo) (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Wet Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2022-05-04